(Q79738986)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16779800%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

title

A phase II trial of dexamethasone, vitamin D, and carboplatin in patients with hormone-refractory prostate cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16779800%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

1 reference

phase II clinical trial

1 reference

1 reference

1 reference

Thomas W Flaig

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16779800%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

Albaha Barqawi

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16779800%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

Gary Miller

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16779800%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

Madeleine Kane

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16779800%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

Chan Zeng

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16779800%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

E David Crawford

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16779800%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

L Michael Glodé

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16779800%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

publication date

1 July 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16779800%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16779800%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

volume

107

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16779800%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16779800%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

page(s)

266-274

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16779800%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

cites work

Cancer statistics, 2004

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21982

7 January 2021

Geographic patterns of prostate cancer mortality. Evidence for a protective effect of ultraviolet radiation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21982

7 January 2021

Hypovitaminosis D in Medical Inpatients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21982

7 January 2021

Induction of apoptosis by vitamin D3 analogue EB1089 in NCI-H929 myeloma cells via activation of caspase 3 and p38 MAP kinase

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21982

7 January 2021

1,25-dihydroxyvitamin D3 and 9-cis-retinoic acid act synergistically to inhibit the growth of LNCaP prostate cells and cause accumulation of cells in G1

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21982

7 January 2021

Effect of carboplatin on response and palliation in hormone-refractory prostate cancer. Swiss Group for Clinical Cancer Research (SAKK).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21982

7 January 2021

Carboplatin in advanced hormone refractory prostatic cancer patients.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21982

7 January 2021

Phase II study of cisplatin for metastatic prostatic carcinoma. An Eastern Cooperative Oncology Group study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21982

7 January 2021

Cytotoxicity of the anticancer agents cisplatin and taxol during cell proliferation and the cell cycle.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21982

7 January 2021

Intestinal calcium absorption in exogenous hypercortisonism. Role of 25-hydroxyvitamin D and corticosteroid dose

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21982

7 January 2021

Importance of increased urinary calcium excretion in the development of secondary hyperparathyroidism of patients under glucocorticoid therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21982

7 January 2021

Enhancement of 1,25-dihydroxyvitamin D3-mediated antitumor activity with dexamethasone

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21982

7 January 2021

High-dose calcitriol and carboplatin in metastatic androgen-independent prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21982

7 January 2021

Metronomic scheduling: the future of chemotherapy?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21982

7 January 2021

Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21982

7 January 2021

A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21982

7 January 2021

Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21982

7 January 2021

Metronomic therapy with cyclophosphamide and dexamethasone for prostate carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21982

7 January 2021

The anti-angiogenic basis of metronomic chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21982

7 January 2021

One-sample multiple testing procedure for phase II clinical trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21982

7 January 2021

Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21982

7 January 2021

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21982

7 January 2021

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21982

7 January 2021

Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21982

7 January 2021

Targeting EGFR in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21982

7 January 2021

Prostate specific antigen levels and clinical response to low dose dexamethasone for hormone-refractory metastatic prostate carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21982

7 January 2021

Glucocorticoids and treatment of prostate cancer: a preclinical and clinical review

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21982

7 January 2021

Treatment of androgen-independent prostate cancer with dexamethasone: a prospective study in stage D2 patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21982

7 January 2021

Dexamethasone does not significantly contribute to the response rate of docetaxel and estramustine in androgen independent prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21982

7 January 2021

Identifiers

DOI

10.1002/CNCR.21982

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16779800%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

1 reference